课题基金 / 基金详情

ADENOSINE AND RETINAL ISCHEMIA

ADENOSINE AND RETINAL ISCHEMIA
腺苷和视网膜缺血
批准号:
2696491
负责人:
STEVEN ROTH
金额:
$26.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-01-01 至 2002-06-30

项目摘要

项目成果

STEVEN ROTH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from applicant's abstract): Retinal ischemia occurs when the oxygen and glucose supply to the retina is interrupted. The pathophysiology involves changes in cellular biochemistry or energy level, blood flow and gene expression. Previous work related to this project has shown, among other things, a complex involvement of adenosine in the pathophysiology of retinal ischemia-reperfusion injury. In addition the phenomenon of retinal pre-conditioning was demonstrated, whereby a brief period of non-damaging ischemia 24 or 72 hours before prolonged ischemia completely preserved retinal function and morphology. This process appears to require protein synthesis and preliminary data shows that adenosine may be a key factor in the initiation of preconditioning. Proposed experiments will use biochemical, morphological and functional measurements to examine mechanisms and effects of adenosine on retinal ischemia. The long-term goal is to characterize endogenous protective mechanisms against ischemic injury in the retina and to use this information to develop clinically relevant treatment strategies of retinal ischemic diseases. Three specific aims are proposed: (1) to characterize basic mechanisms and limitations of preconditioning and the role of adenosine as an initiator of preconditioning; (2) to examine the effect of altered adenosine metabolism in retinal function and structure during severe ischemia; and (3) to test mechanisms of adenosine receptor-mediated protection against retinal ischemic injury. These studies are relevant to acute disease states such as retinal arterial occlusion, or to chronic diseases that also result in ischemia, such as diabetic retinopathy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injury
Mesenchymal stem cell extracellular vesicles for ischemic retinal damage
VRC: Engineered extracellular vesicles for mild TBI-induced retinal injury
海外基金